Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Pha...
Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price t...
− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran's Differentiated Prof...
Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds m...
Piper Sandler analyst Edward Tenthoff reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the pric...
Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and raises the price target fro...
Alnylam stock fell after a strong Q3 with $2.90 EPS and $1.25 billion revenue, a subpoena disclosure, and raised 2025 sales gui...
